Related Experiment Video
Updated: Apr 8, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Vascular endothelial growth factor polymorphisms and lung cancer risk
Junli Fan1, Weiguo Zhang1, Caipeng Lei1
1Department of Oncology Surgery, The First Affiliated Hospital of Henan University of Science and Technology Luoyang 471003, Henan, China.
Abstract:
The VEGF polymorphisms has been implicated in the susceptibility to lung cancer, but the results are not conclusive. The aim of this study is to investigate the association between the VEGF polymorphisms and the risk of lung cancer by meta-analysis. We searched PubMed, Embase, CNKI and Wanfang databases. A total of 7 case-control studies were included in this meta-analysis. We found that VEGF rs833061 polymorphism showed no significant association with lung cancer risk. Subgroup analysis on race suggested that CC genotype was significantly associated with lung cancer risk in Asian population. We found that VEGF rs699947 polymorphism showed significant association with lung cancer risk. Subgroup analysis on race showed that VEGF rs699947 polymorphism increased lung cancer risk in Asians. In conclusion, this meta-analysis suggested that the VEGF rs699947 is associated with increased risk of lung cancer.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Regulation of Angiogenesis and Blood Supply
Single Nucleotide Polymorphisms-SNPs
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetics of Drug Metabolism: Overview

